Argenica Therapeutics Limited (ASX:AGN)

Argenica Therapeutics Revenue

In the fiscal year ending June 30, 2026, Argenica Therapeutics had annual revenue of 5.70M AUD with 77.26% growth. Argenica Therapeutics had revenue of 626.74K in the half year ending December 31, 2025, a decrease of -73.36%.

• Revenue: 5.70M
• Revenue Growth: +52.87%
• P/S Ratio: 4.28
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 24.41M

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2026	5.70M	2.48M	77.26%
Jun 30, 2025	3.21M	615.81K	23.70%
Jun 30, 2024	2.60M	848.04K	48.46%
Jun 30, 2023	1.75M	1.49M	575.38%
Jun 30, 2022	259.10K	-36.98K	-12.49%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 26, 2026

Data Sources Report a data error